Summary sheet
Guerbet S.A.
The project focuses on the development of new or improved contrast agents for medical imaging. If successful, they will improve the anatomic visualisation of human organs, the detection of pathologies as well as the functional evaluation of certain organs.
The project helps to strengthen the knowledge base and, by default, the market position of a European specialist pharmaceutical company that operates in the segmented global market for medical imaging. Furthermore, the project is expected to increase the small number of contrast agents that are currently on the market.
The R&D activities encompassed within this project will not materially change current R&D practices and will be carried out within existing facilities, making use of existing laboratories, pilot plants, clinical centres etc. An EIA required by EU Directive 97/11 as amended by Directive 2003/35 is therefore not required. Compliance of R&D activities with relevant EU environmental legislation will be verified during appraisal.
The promoter is a private company not operating in the Utilities sector, and is thus not covered by EU directives on procurement.